The Safety and Efficacy of Standard-Dose versus Low-Dose Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Left Atrial Appendage Thrombus

Figure 1

The distribution of dabigatran and rivaroxaban usage in the standard-dose and low-dose groups. The doses of NOACs for patients in the standard-dose group were dabigatran 150 mg (twice daily) and rivaroxaban 20 mg (once daily), while those for patients in the low-dose group were dabigatran 110 mg (twice daily) and rivaroxaban 15 mg (once daily).